Results 281 to 290 of about 847,596 (330)

The Use of Enhanced Analytical Pipelines for the Characterization of Poly(A) and Poly(A)-LNP Formulation Critical Quality Attributes. [PDF]

Mol Pharm
Davidson CG, Kapsali E, Ioannou S, Kopilovic B, Hussain M, Perrie Y, Rattray Z.   +6 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

BRAND ASSOCIATION PERMEN DAVOS ROLL PACK PADA KONSUMEN (Studi Deskriptif Kualitatif tentang Brand Association Permen Davos Roll Pack pada Konsumen di Desa Kandanggampang Kabupaten Purbalingga) [PDF]

, 2014
Marcy Marcy
openalex  

The impact of influencer marketing in the tourism industry: A digital marketing perspective. [PDF]

PLoS One
Babu MA, Urmi HA, Tofayel AH, Sabuj MMI, Alam MTU.   +4 more
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

How Loud is Minimally Invasive Spine Surgery? Identifying Intraoperative Risk of Hearing Loss. [PDF]

Global Spine J
Ehrlich AM, Kush S, Simon CZ, Zhao ER, Asada T, Korsun MK, Owusu-Sarpong S, Colon LF, Mushbarash F, Singleton Q, Kazarian GS, Qureshi SA, Iyer S.   +12 more
europepmc   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

MarkeTrak 2025: Consumer Perspectives on Hearing Health in an Evolving Market. [PDF]

Semin Hear
Dobyan B, Kihm J.
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

A rare case of anaphylaxis caused by mint-containing toothpaste in a child: A case report. [PDF]

Asia Pac Allergy
Tan ASH, Lee MP, Goh SH, Tan LL, Chong KW.   +4 more
europepmc   +1 more source